Aerpio Pharmaceuticals

Aerpio Pharmaceuticals Completes Patient Enrollment in TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy

February 9th, 2018

Read the press release.